Corporate ProfileTocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 2/3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA.
NASDAQ GS TOCA (Common Stock)
$16.64 + 0.67
05/25/17 4:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
Tocagen Reports First Quarter 2017 Financial and Business Results05/23/17
Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting05/11/17
Tocagen Announces Closing of Initial Public Offering and Exercise of the Underwriters' Option04/19/17